GoAI
Get started
Opus Genetics, Inc. logo

Opus Genetics, Inc.

IRD

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$4.05

−$0.07 · -1.70%

Aug 21, 4:00 PM ET

IRD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

37

Expensive

Momentum

52

Neutral

Sentiment

65

Bullish

Risk resilience

44

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
George Magrath
Listed since
Jan 19, 2015
Employees
28

Market position

Day range

Current $4.05

52-week range

Current $4.05

Open
$4.16
Previous close
$4.12
Volume
1.05M
1.11× average
Average volume
950.05K
Average daily volume
Market cap
334.39M USD
Beta
0.58
Market reference 1
50-day average
$3.7458
+8.12% above average
200-day average
$3.5906
+12.80% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.21B USD
P/E (TTM)
-3.19×
P/B (TTM)
-29.78×
P/S (TTM)
33.93×
EV / EBITDA
-25.08×
Earnings yield
-3.97%
Free cash flow yield
-2.82%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
99.87%
Operating margin
-513.47%
Net margin
-1091.82%
Return on equity
-323.11%
Return on assets
-98.70%
Return on invested capital
-90.90%

Financial health

Debt / equity
-2.69×
Current ratio
6.43×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1073%-2818%-6708%-10598%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2021: -3854.84%Operating margin, FY2022: 45.74%Operating margin, FY2023: -55.45%Operating margin, FY2024: -564.72%Operating margin, FY2025: -271.90%Net margin, FY2021: -9625.30%Net margin, FY2022: 44.89%Net margin, FY2023: -52.42%Net margin, FY2024: -523.40%Net margin, FY2025: -349.33%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2021 -3854.84%. Operating margin FY2022 45.74%. Operating margin FY2023 -55.45%. Operating margin FY2024 -564.72%. Operating margin FY2025 -271.90%. Net margin FY2021 -9625.30%. Net margin FY2022 44.89%. Net margin FY2023 -52.42%. Net margin FY2024 -523.40%. Net margin FY2025 -349.33%.

Income trends

Revenue

14.2M USD+29.15%

Operating income

−38.6M USD+37.82%

Net income

−49.59M USD+13.80%
Income trends across reported periods50.04M USD9.27M USD−31.5M USD−72.27M USDRevenue, FY2021: 589K USDRevenue, FY2022: 39.85M USDRevenue, FY2023: 19.05M USDRevenue, FY2024: 10.99M USDRevenue, FY2025: 14.2M USDOperating income, FY2021: −22.71M USDOperating income, FY2022: 18.23M USDOperating income, FY2023: −10.56M USDOperating income, FY2024: −62.07M USDOperating income, FY2025: −38.6M USDNet income, FY2021: −56.69M USDNet income, FY2022: 17.89M USDNet income, FY2023: −9.99M USDNet income, FY2024: −57.53M USDNet income, FY2025: −49.59M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 589K USD. Revenue FY2022 39.85M USD. Revenue FY2023 19.05M USD. Revenue FY2024 10.99M USD. Revenue FY2025 14.2M USD. Operating income FY2021 −22.71M USD. Operating income FY2022 18.23M USD. Operating income FY2023 −10.56M USD. Operating income FY2024 −62.07M USD. Operating income FY2025 −38.6M USD. Net income FY2021 −56.69M USD. Net income FY2022 17.89M USD. Net income FY2023 −9.99M USD. Net income FY2024 −57.53M USD. Net income FY2025 −49.59M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue14.2M USD10.99M USD19.05M USD39.85M USD589K USD
Gross profit14.2M USD10.99M USD19.05M USD39.85M USD589K USD
Research and development30.81M USD26.85M USD17.65M USD14.36M USD15.17M USD
Selling, general, and administrative21.98M USD18.22M USD11.96M USD7.27M USD8.12M USD
Operating expenses52.8M USD73.07M USD29.61M USD21.62M USD23.29M USD
Interest expense1.47M USD—1.33M USD9K USD2K USD
Depreciation and amortization53K USD10K USD6K USD4K USD4K USD
Operating income−38.6M USD−62.07M USD−10.56M USD18.23M USD−22.71M USD
Net income−49.59M USD−57.53M USD−9.99M USD17.89M USD−56.69M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

8 institutions
RBC CapitalmaintainOutperform
WedbushmaintainOutperform
Jones TradingmaintainBuy

IRD peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding IRD

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
8.31M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
5.47M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.42M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
2.07M
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.11M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
766.81K
Weight
0.05%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF logoGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC
Market value
364.94K
Weight
0.03%
AUM
1.08B USD
Expense ratio
0.20%
Price / 1D
$91.32+0.82%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
332.64K
Weight
0.01%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%

Continue in GoAI

Research IRD

research.disclaimer